Pancreatic Adenocarcinoma

The CyberKnife is well-poised to improve the local control rates−this is accomplished with high doses per fraction delivered via a highly conformal approach; improvements in systemic therapy are also necessary, which can easily be sequenced into the treatment as the CyberKnife treatment is of short duration.

CyberKnife® Monotherapy for Low-Risk Prostate Cancer

The CyberKnife® System successfully reproduced an HDR-like dose distribution, delivering treatment in a minimally invasive fashion.

Low-Risk Organ-Confined Prostate Cancer

CyberKnife monotherapy produced an early and stable reduction in PSA in a patient with low-risk organ-confined prostate cancer with minimal acute urinary toxicities and no noted chronic toxicities.

Non-Invasive Stereotactic Radiosurgical Treatment of Non-Small Cell Lung Cancer

This patient had an excellent initial outcome with the CyberKnife System using Xsight® Lung Tracking; the patient was able to undergo treatment completely non-invasively without implanted fiducials or markers.